SARS-CoV-2 & Flu Multiplexed Solutions

Whether your laboratory is utilizing multiplex or sequential testing workflows, AccuPlex™ offers quality solutions with targets for SARS-CoV-2, influenza A/B and respiratory syncytial virus (RSV). These quality solutions are designed to challenge the entire molecular test procedure ensuring clinical laboratories can have confidence in their assay results. 

AccuPlex™ Verification Panels are optimized for assay verification at installation by documenting test performance along the assay’s range, enabling laboratories to establish lower limits of detection, perform assay comparisons, and evaluate staff proficiency.

Click here for bulk quantities or custom requests

Click here to learn more about SARS-CoV-2 Molecular Solutions.

 SARS-CoV-2 Quality Solutions:

• Non-infectious and replication deficient, enables safe handling in contrast to viral samples
• Fully-extractable with a real viral protein coat; superior to “naked” transcribed RNA
• Optimized for assay verification and day-to-day performance monitoring
• 2 year stability at 2 - 8°C 

 

LGC SeraCare’s AccuPlex recombinant material serves as a true full process molecular control for your diagnostic assays. Compatible with multiplexed RT-PCR and NGS-based assays, AccuPlex custom recombinant materials are constructed with a replication-deficient mammalian virus, producing a safe, non-infectious material (Figure 1 ). With a protein coat and lipid bilayer, these mammalian virus-based reference materials resemble the complexity of virus targets found in true patient samples.

 

FIGURE 1: 1) RNA sequence from the pathogenic virus of interest is chosen. 2) DNA synthesis and cloning occur to produce the recombinant RNA. 3) Recombinant RNA and helper RNA are co-transfected into the mammalian cells, allowing the encapsulation of recombined RNA. 4) Exocytosis of the mature enveloped non-infectious and replication deficient RNA virus containing the assay target RNA sequence of interest.